Ruxolitinib is a janus kinase inhibitor (JAK inhibitor) with selectivity for subtypes JAK1 and JAK2. Ruxolitinib inhibits dysregulated JAK signaling associated with myelofibrosis. JAK1 and JAK2 recruit signal transducers and activators of transcription (STATs) to cytokine receptors leading to modulation of gene expression.

Sargramostim is primarily used for myeloid reconstitution after autologous or allogeneic bone marrow transplantation. It is also used to treat neutropenia induced by chemotherapy during the treatment of acute myeloid leukemia. It also used as a medical countermeasure for treating people who have been exposed to sufficient radiation to suppress bone marrow myelogenesis.

Sarilumab binds to both soluble and membrane-bound interleukin6 (IL-6) receptors (sIL-6R and mIL-6R) and has been shown to inhibit IL-6-mediated signaling through these receptors. IL-6 is a pleiotropic pro-inflammatory cytokine produced by a variety of cell types including T-cells and B-cells, lymphocytes, monocytes, and fibroblasts. IL-6 has been shown to be involved in diverse physiological processes such as T-cell activation, induction of immunoglobulin secretion, initiation of hepatic acute phase protein synthesis, and stimulation of hematopoietic precursor cell proliferation and differentiation.

Selinexor is an inhibitor of chromosome region maintenance 1 (CRM1), the major export factor for proteins from the nucleus to the cytoplasm. Binding irreversibly inactivates CRM1-mediated nuclear export of cargo proteins such as growth regulatory proteins.

FDA-approved since 2019, approved to treat multiple myeloma.

SYLVANT is indicated for the treatment of patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.

Thalidomide is used as a first-line treatment in multiple myeloma in combination with dexamethasone or with melphalan and prednisone, to treat acute episodes of erythema nodosum leprosum, and for maintenance therapy. The bacterium that causes tuberculosis (TB) is related to leprosy. Thalidomide may be helpful in some cases where standard TB drugs and corticosteroids are not sufficient to resolve severe inflammation in the brain.

CYNK-001 is a cell-based therapy comprised of natural killer (NK) cells derived from placental stem cells. These cells can be frozen, culture-expanded, and administered to patients. NK cells play a major role in the body getting rid of virally infected cells, including those infected with SARS-CoV-2.

Thymosins are a family of small proteins that are found in many animal (and human) tissues and have a wide array of functions. One such function is their ability to regulate cellular immunity in sepsis patients.

Даларгин подавляет протеолиз, заживляет трофические язвы и защищает органы и ткани (легких, печени, поджелудочной железы). При комплексной интенсивной терапии полиорганной недостаточности Даларгин существенно снижает тяжесть респираторного дистресс-синдрома.